<DOC>
	<DOCNO>NCT00002554</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Monoclonal antibody combine radioactive substance give prior bone marrow transplantation may kill cancer cell . PURPOSE : Phase II trial study effectiveness radiolabeled monoclonal antibody give prior bone marrow transplantation treat patient acute myelogenous leukemia .</brief_summary>
	<brief_title>Monoclonal Antibody Followed Bone Marrow Transplantation Treating Patients With Acute Myelogenous Leukemia Remission First Relapse</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall disease-free survival toxicity associate busulfan/cyclophosphamide ( BU/CTX ) plus 131I-labeled BC8 antibody ( 131I-BC8 ) follow HLA-identical related marrow transplant patient acute myelogenous leukemia first second remission untreated first relapse . II . Study factor may influence biodistribution 131I-BC8 patient population , include marrow cellularity , level antigen expression leukemic cell ( relapsed patient ) , degree antigen saturation antibody . III . Determine efficacy BU/CTX patient first remission unable receive radiolabeled antibody , e.g. , patient HAMA-positive , tolerate antibody test infusion , unfavorable antibody biodistribution , antibody unavailable . OUTLINE : Radioimmunotherapy plus 2-Drug Cytoreductive Chemotherapy follow Bone Marrow Transplantation , indicate , CNS Therapy . Iodine-131-labeled Monoclonal Antibody BC8 ( anti-CD45 ) , 131I-BC8 ; plus Busulfan , BU , NSC-750 ; Cyclophosphamide , CTX , NSC-26271 ; follow Allogeneic Bone Marrow , ABM ; , indicate , Intrathecal Methotrexate , IT MTX , NSC-740 . PROJECTED ACCRUAL : It anticipate 30 patient first remission , 30 patient untreated first relapse , 15 patient second remission accrue 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myelogenous leukemia first second remission untreated first relapse Documented CD45 expression leukemic cell require patient relapse Phenotyping required patient remission ; patient may leukemia previously document CD45 negative Circulating blast count le 10,000 ( control hydroxyurea similar agent allow ) Genotypically phenotypically HLAmatched related marrow donor require No donor mismatch 1 HLA antigens No psychologic , physiologic , medical contraindication donation No high risk anesthesia age medical problem No HIV seropositive donor PATIENT CHARACTERISTICS : Age : 16 55 Performance status : Not specify Life expectancy : Greater 60 day Hematopoietic : Not applicable Hepatic : Bilirubin le 1.5 mg/dl No risk develop venoocclusive disease liver ( i.e. , current evidence hepatitis manifest SGOT great 1.5 x ULN ) Renal : Creatinine le 2.0 mg/dl Other : No HIV seropositivity No major infection PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy maximally tolerated level normal organ</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
</DOC>